<DOC>
	<DOCNO>NCT01247701</DOCNO>
	<brief_summary>In study , investigator use busulfan cyclophosphamide ( BuCy ) backbone addition fludarabine preparative Stem Cell Transplant ( SCT ) regimen . As attempt improve engraftment rate reduce infection , investigator go incorporate fludarabine condition regimen . The use BuCy backbone widely use comparable total body irradiation cyclophosphamide ( Cy/TBI ) regimen . Encouraging data add fludarabine SCT regimen report . A fludarabine-based , condition regimen , adequate immunosuppressive activity could conceivably allow engraftment stem cell alternative donor hematologic malignancy patient acceptable engraftment rate low transplant-related mortality . Regimen-related toxicity believe major contribute factor GVHD . Therefore approach may also lead reduce GVHD , investigator suggest . In attempt decrease rate viral infection reactivation , investigator avoid ATG ( Thymoglobulin ) / Campath ( anti-CD52 ) , instead administer Mycophenolate Mofetil ( MMF ) . The addition fludarabine compensate increase risk graft failure removal ATG/Campath . The investigator anticipate removal ATG/Campath facilitate immune reconstitution efficiently receive UCBT .</brief_summary>
	<brief_title>Umbilical Cord Blood Transplant Children With Myeloid Hematological Malignancies</brief_title>
	<detailed_description>The follow give condition regimen transplant : BUSULFAN : Busulfan ( intravenous BUSULFEX ) dose follow : patient &lt; 12 kg : 1.1 mg/kg/dose IV every 6 hour 16 dos total ; patient &gt; 12 kg : 0.8 mg/kg/dose IV every 6 hour 16 dos . Administration pharmacokinetic monitoring perform per standard practice . Anticonvulsants give accordance standard Blood Marrow Transplant Program recommendation . CYCLOPHOSPHAMIDE : Cyclophosphamide ( 50 mg/kg/dose ) give IV Days -5 , - 4 , -3 , -2 2 hour . The total dose give 4 day 200 mg/kg . Mesna give accordance standard Blood Marrow Transplant . FLUDARABINE : Fludarabine 40 mg/m2 give IV daily 1 hour 3 day . Preparation , administration monitoring accord standard practice procedure . POST-TRANSPLANT IMMUNOSUPPRESSION : - CSA begin Day -3 . For child &lt; 40 kg , initial dose 2.5 mg/kg IV 2 hour every 12 hour . Dose adjustment make maintain level 200 ng/mL . Levels do Day 0 clinical indicate . CSA taper per institutional SOP . Once patient tolerate oral medication normal gastrointestinal transit time , CSA convert oral form . - MMF begin Day 0 dose 15 mg/Kg IV orally TID , discontinue Day +45 unless GVHD present . CNS Disease : Patients CNS relapse primary CNS disease symptomatic associate radiological change receive additional irradiation craniospinal axis . SUPPORTIVE CARE : - Supportive care provide per standard practice Blood Marrow Stem Cell Transplant program Texas Children 's Hospital , include prophylactic therapeutic clinical care issue . These practice may modify necessary individual patient order provide optimum care particular patient . - IVIG : Intravenous immunoglobulin ( 500 mg/kg per dose ) give monthly discontinuation GVHD therapy documentation antibody production . - CB-CTLs : Patients enrol protocol may also eligible infusion CB-derived multivirus-specific CTL provide virus-specific immune reconstitution treatment viral infection CBT . EVALUATIONS DURING THE STUDY : Screening Procedures ; Pre-HCT : - Physical examination - Pregnancy test - Complete blood count chemistry - Electrocardiogram - Viral test - Bone marrow aspirate biopsy/Lumbar puncture - Renal Function ( GFR ) - Lumbar puncture perform - Pulmonary Function test EVALUATIONS BETWEEN DAY 0 AND DAY 100 : - Physical examination - Complete blood count chemistry - Peripheral blood STRs FISH analysis molecular diagnostics - Lymphocyte phenotype test lymphoproliferative response - Bone marrow aspirate biopsy assessment leukemia status UCB engraftment - Lumbar puncture - Immunoglobulins EVALUATIONS AFTER DAY 100 : - Physical examination - Complete blood count chemistry - Peripheral blood assessment engraftment STRs FISH analysis enzyme level - Echocardiograph LVEF - Bone marrow aspirate biopsy assessment leukemia status UCB engraftment - Lymphocyte phenotype testing ( CD3 , CD4 , CD8 , CD14 , CD19 CD56 ) lymphoproliferative response - Immunoglobulins FOLLOW-UP INTERVAL : Patients see hospital everyday discharge . After discharge hospital , patient follow BMT clinic regular basis recommend primary physician .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients myeloid hematologic malignancy ( acute myelogenous leukemia , secondary myelogenous leukemia myelodysplastic syndrome ) unlikely cure standard chemotherapy . This include patient relapsed standard chemotherapy treatment patient first remission unfavorable prognostic feature . Related Unrelated Umbilical Cord Blood Unit 01 antigen mismatch HLAA B ( low resolution ) DRB1 ( high resolution ) , total nucleate cell dose â‰¥ 4 x 10^7/kg . Lansky/Karnofsky score least 60 . Written inform consent and/or sign assent line patient , parent guardian . Negative pregnancy test , applicable . Patients uncontrolled infection . For bacterial infection , patient must receive definitive therapy sign progress infection 72 hour prior enrollment . For fungal infection , patient must receive definitive systemic antifungal therapy sign progress infection 1 week prior enrollment . Progressing infection define hemodynamic instability attributable sepsis new symptom , worsen physical sign radiographic finding attributable infection . Persisting fever without sign symptom interpret progress infection . Severe renal disease ( Creatinine &gt; 3X normal age ) . Severe hepatic disease ( direct bilirubin &gt; 3 mg/dL SGOT &gt; 500 ) . Patient DLCO &lt; 50 % predict FEV1 &lt; 50 % predict , applicable . Patients symptomatic cardiac failure unrelieved medical therapy evidence significant cardiac dysfunction echocardiogram ( shorten fraction &lt; 20 % ) . HIV positive .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>UCB</keyword>
	<keyword>Umbilical Cord Blood</keyword>
	<keyword>Transplant</keyword>
	<keyword>Umbilical Cord Blood Transplant</keyword>
	<keyword>Cord Blood Stem Cell Transplantation</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Myeloid Hematological Malignancies</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
</DOC>